NCT05246618View on ClinicalTrials.gov

FIH Phase I/IIa Trial Evaluating Safety of TUM012 to Minimize Ischemic Reperfusion Injury in Kidney Transplantation

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

May 14, 2024

Conditions
Ischemia-reperfusion InjuryKidney Transplant; Complications
Interventions
DRUG

TUM012

Ex-vivo infusion

DRUG

Placebo

Ex-vivo infusion

Trial Locations (1)

SE-205 02

Skane University Hospital, Malmo

Sponsors
All Listed Sponsors
collaborator

CTC Clinical Trial Consultants AB

INDUSTRY

collaborator

Region Skane

OTHER

lead

iCoat Medical AB

INDUSTRY